May 15th 2024
For Melanoma and Skin Cancer Awareness Month, Nayoung Lee, MD, discussed evolving paradigms in skin cancer diagnosis and prevention.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
From the Chairman: Moving Forward With Bold Innovation
July 14th 2016As I write this, the 2016 ASCO conference has just concluded in Chicago. And, as is typical with this event, the amount and level of groundbreaking research and information presented at this year's conference is nothing less than staggering in its scope, innovation, and promise.
Read More
The Significance of the Ipilimumab/Nivolumab Findings in Melanoma
July 12th 2016Norman E. Sharpless, MD, professor of Medicine and Genetics, chair, the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center, UNC School of Medicine, discusses the significance of the ipilimumab/nivolumab findings from the CheckMate-069 trial for melanoma.
Watch
Hedgehog Inhibitors Show Significant Benefit in Advanced Basal Cell Carcinoma
July 12th 2016For patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy, the hedgehog/smoothened inhibitors sonidegib and vismodegib have both shown significant benefit.
Read More
Beyond PD-1/CTLA-4: Immunotherapy Combos Explore New Ground
June 28th 2016A variety of dual immunotherapy combination regimens are currently under exploration that could build upon the success seen with the addition of the CTLA-4 inhibitor ipilimumab (Yervoy) to PD-1 blockade with nivolumab (Opdivo) for the treatment of patients with advanced melanoma.
Read More
Considerations for Single-Agent Versus Combo Melanoma Immunotherapy
June 22nd 2016The combination of ipilimumab (Yervoy) and nivolumab (Opdivo) continues to show promise, with recent data demonstrating a 26% improvement in overall survival (OS) with the 2 drugs compared with ipilimumab alone for patients with advanced melanoma.
Read More
Nivolumab/Ipilimumab Combo Gains NICE Approval for Melanoma Treatment
June 22nd 2016The National Institute for Health and Care Excellence (NICE) has approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for patients with metastatic melanoma, which allows the combination to be used within the National Health Service (NHS).
Read More
Sequencing Agents for the Treatment of Patients With Melanoma
June 22nd 2016Antoni Ribas, MD, PhD, professor of Hematology and Oncology and director of the Tumor Immunology Program Area at UCLA Jonsson Comprehensive Cancer Center, discusses how to appropriately sequence therapies for patients with melanoma.
Watch